Juan A. Garcia-Velasco, M.D.
Volume 98, Issue 6, Pages 1356-1358, December 2012
The use of AIs in IVF patients is still controversial. Although the biological plausibility of the capacity of AIs in IVF patients with a poor response to COH to modulate androgens and improve cycle outcome is promising, still results should be interpreted with caution, as they need to prove their efficacy in randomized trials. They are an effective drug to drastically reduce circulating estrogen levels in those patients at risk of OHSS, thrombosis or hormonal-dependent diseases.
Read the full text at: http://www.fertstert.org/article/S0015-0282(12)02261-3/fulltext